TY  - JOUR
T1  - Coronary events with lipid-lowering therapy: The afcaps/texcaps trial—reply
AU  - Downs JR, Gotto, Jr AM, Clearfield M, Weis S
Y1  - 1999/02/03
N1  - 10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203
JO  - JAMA
SP  - 414
EP  - 419
VL  - 281
IS  - 5
N2  - 
Prespecified treatment by subgroup interactions were performed to
show consistency between the subgroups and the overall results, not to
establish efficacy within the subgroups. It is not statistically
appropriate to perform between-treatment comparisons within subgroups
(eg, women) when there is no interaction between the subgroup factor
and treatment, as was the case for sex and treatment in
AFCAPS/TexCAPS (ie, similar treatment effects for men and
women). However, if this test is performed, there is also inadequate
sample size to find a significant effect in women
(n=997, RR=0.54, 95% confidence
interval, 0.22-1.35). As AFCAPS/TexCAPS is the first primary
prevention study with a statin to include women, we considered it
important to report that treatment did not appear to work differently
or less effectively in women.

SN  - 0098-7484
M3  - doi: 10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203
UR  - http://dx.doi.org/10-1001/pubs.JAMA-ISSN-0098-7484-281-5-jbk0203
ER  -